• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Thursday 06/21/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

MSLP

  • 3:46 PM

    DENVER, Sept. 23, 2016 /PRNewswire/MSLP, — MusclePharm Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically driven, performance-lifestyle sports nutrition company, hosted the First Annual Submit Cancer Jiu-Jitsu Charity Event in August. With over 450 attendees and raising over $60,000 for the Children’s Hospital Foundation Colorado, 100% of the proceeds went back to charity with MusclePharm funding the event. “We are focusing on the things that define who we are as a brand: label and company transparency, science, customer service,

    Read more
  • 2:53 PM

    DENVER, March 16, 2016, MSLP, /PRNewswire/ — MusclePharm Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically-driven, performance lifestyle sports nutrition company, today announced Brad Pyatt has resigned from his position as CEO and will also leave the Company’s Board of Directors. Executive Chairman Ryan Drexler has been appointed Interim CEO and President. The Company has begun a search for a replacement that will be overseen by the board. “Brad has been a valuable innovator and contributor to MusclePharm, both as

    Read more
  • 4:44 PM

    Jan 14, 2016, MSLP,  OTC Disclosure & News Service – MusclePharm Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically-driven, performance lifestyle sports nutrition company, today announced the completion of a financing agreement with Prestige Capital Corporation (“Prestige Capital”) in the initial amount of $10 million. The financing agreement is a major step towards strengthening the Company’s financial position. The agreement with Prestige Capital allows the Company to use its receivables to finance up to a total of $10 million. The Company

    Read more
  • 2:59 PM

    http://www.publicwire.comNuvilex Retains TD2 to Conduct Preclinical and Clinical Studies SILVER SPRING, Apr 01, 2014 (GLOBE NEWSWIRE via COMTEX) — Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Master Services Agreement with Translational Drug Development (TD2) pursuant to which TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex’s pancreatic cancer and other treatments utilizing Cell-in-a-Boxtechnology. “The Nuvilex team

    Read more
Public Wire Banner